All articles tagged with #melanoma
Using intravital two-photon microscopy, researchers watched CD169-expressing macrophages in the skin’s hypodermis engulf live melanoma cells without T or B cells, a finding that depletion of these macrophages worsened tumor growth and that similar macrophage populations were found at human melanoma margins—suggesting a way to turn ‘cold’ tumors ‘hot’ and possibly enhance responses to immune checkpoint inhibitors.
Regeneron’s phase 3 trial of fianlimab with Libtayo failed to beat Merck’s Keytruda as first-line therapy for unresectable melanoma, missing the primary endpoint of progression-free survival despite a numerical edge at the high dose; analysts say late separation of survival curves drove the non-significant result, signaling renewed pipeline pressure even as Regeneron pursues potential salvage paths (head-to-head vs Opdualag) and continues other programs (Factor XI, cemdisiran-pozelimab) as future catalysts.
Regeneron disclosed a late-stage trial evaluating a Libtayo-based combination for melanoma failed to meet its endpoints when compared with Merck’s Keytruda, sparking investor scrutiny of Regeneron’s cancer-immunotherapy program.
Researchers uncovered a two-part genetic strategy used by melanoma cells to bypass cellular aging: mutations that boost telomerase production via TERT and concurrent promoter mutations in ACD that recruit telomerase to telomeres through the shelterin component TPP1, lengthening chromosome caps and enabling extended cell division. This explains the unusually long telomeres seen in melanoma and points to a potential new therapeutic target.
Dermatologists warn that clothing choices can influence sun exposure and skin-cancer risk during Skin Cancer Awareness Month. Opt for UPF 50+ fabrics (like polyester, nylon, merino wool, denim, corduroy), prefer darker/brighter colors, and choose looser fits over tight garments; avoid crochet/mesh that let UV through. Don wide hats and UV umbrellas, and apply sunscreen daily, since UV exposure accumulates over a lifetime.
Melanoma Monday highlights that skin cancer is common and early detection saves lives: a MedStar Health survey shows many adults have never had a doctor’s skin check, and many don’t know melanoma is the deadliest form or that it can become dangerous quickly. The article reiterates the ABCDE rules (asymmetry, borders, color, diameter, evolving) for spotting suspicious moles and emphasizes reapplying sunscreen every two hours, especially during water or sweaty activity, to reduce risk and improve outcomes when caught early.
New findings from Fox Chase Cancer Center show melanoma spread varies with age: lowest in young mice, highest in middle-aged, then dropping in old age, linked to gamma-delta T cells. The study suggests aging significantly alters cancer immunity and that most preclinical work in young animals may hinder translating therapies to older patients.
Famed ESPN college basketball announcer Dick Vitale, 86, disclosed that biopsy results confirmed melanoma in the lung and liver, and he will start immunotherapy. This marks his fifth cancer diagnosis after previously beating melanoma, lymphoma, vocal-cord cancer and lymph-node cancer. He recently returned to ESPN ahead of March Madness 2025 and remains optimistic, while continuing his pediatric cancer fundraising, including the 21st Dick Vitale Gala on May 1 in Sarasota that aims to raise about $12 million; the gala has already raised more than $105 million for cancer research.
Famed ESPN college basketball broadcaster Dick Vitale has biopsy-confirmed melanoma in his lung and liver cavity and will begin immunotherapy. The 86-year-old is fighting his fifth cancer, after previously beating melanoma, lymphoma, vocal-cord cancer and cancerous lymph nodes; he remains upbeat, continues his ESPN work, and plans to raise funds for pediatric cancer research through his gala.
ESPN basketball icon Dick Vitale, 86, reveals melanoma has again struck, this time in his lungs and liver cavity, and will begin immunotherapy next week. He says he’s beaten multiple cancers before and remains confident he’ll win this battle, while continuing his pediatric cancer fundraising efforts.
The FDA rejected Replimune’s RP1 melanoma candidate for a second time, citing that the Ignyte trial data do not show substantial evidence of effectiveness and that new trial data are unpersuasive (only about 10% of planned patients treated and no prespecified progression-free survival data). The agency’s ruling leaves RP1’s future uncertain and prompted a roughly 20% drop in Replimune’s stock.
The FDA has once more rejected Replimune’s engineered virus therapy for advanced melanoma, a decision that underscores the ongoing debate over tightening agency standards amid leadership changes; the treatment is designed to boost the immune system’s attack on skin cancer, but regulators say the data remain insufficient.
Dermatologists say the number-one sign of all common skin cancers—basal cell, squamous cell, and melanoma—is a change in an existing spot or the appearance of new skin lesions; prompt evaluation is crucial, as early detection greatly improves outcomes, with melanoma survival over 99% when diagnosed before it spreads beyond the skin.
Dermatologists say the number-one sign of skin cancer—across all types—is a change in a spot on the skin, such as growth, bleeding, itching, tenderness, or a new lesion. Early detection is crucial: treating basal and squamous cell cancers is highly effective when found early, and melanoma has a survival rate over 99% when confined to the skin, highlighting the importance of monitoring skin changes and seeking evaluation promptly.
The FDA has withdrawn a proposed rule that would have banned tanning bed use for anyone under 18 and required parental waivers for adults, leaving regulation up to states; UV exposure from sunlamps raises skin-cancer and melanoma risk, and devices can emit up to 15 times more UV than sunlight. Warnings remain on devices, but experts debate whether warnings alone are enough without a federal ban while the agency pursues other sunlamp regulations in the future.